Drug resistance represents the major reason of pharmacological treatment failure. It is
supported by a broad spectrum of mechanisms, whose molecular bases have been …

Farnesyltransferase inhibitors (FTIs) have mainly been used in cancer therapy. However,
more recently, investigations on these inhibitors revealed that FTIs can be used for the …

Ovarian cancer (OC) has the highest mortality of all gynaecological cancers. Early diagnosis
offers an approach to achieving better outcomes. We conducted a blinded‐evaluation of …

The mechanisms underlying tyrosine kinase inhibitor (TKI) resistance in chronic myeloid
leukemia (CML) patients lacking explanatory BCR-ABL1 kinase domain mutations are …

5,348,945 A 9, 1994 Berberian et al. 5,830.464 A 11/1998 Srivastava 5.948, 646 A 9, 1999
Srivastava 5,985,270 A 11/1999 Srivastava 6,007,821 A 12/1999 Srivastava et al. 6,139,841 …

The present invention concerns a method for modulating the enzymatic activity of an
enzyme, wherein said enzyme inter acts with BMP said method comprising the step of …

Cancer stem cells (CSCs) have been proposed as central drivers of tumor initiation,
progression, recurrence, and therapeutic resistance. Therefore, identifying stem-like cells …

Background Manumycin exhibits an antitumor effect in a variety of cancer cell lines,
including prostate cancer cell lines (DU145 and PC-3). Our previous studies demonstrated …

US9289472B2 - Use of HSP70 as a regulator of enzymatic activity - Google Patents
US9289472B2 - Use of HSP70 as a regulator of enzymatic activity - Google Patents Use of …

US10543204B2 - Use of Hsp70 as a regulator of enzymatic activity - Google Patents
US10543204B2 - Use of Hsp70 as a regulator of enzymatic activity - Google Patents Use of …